We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
-27.93%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$108M
AUM Growth
-$58.1M
(-35%)
Cap. Flow
+$214K
Cap. Flow % of AUM
Cap. Flow %
0.2%
Top 10 Holdings %
Top 10 Hldgs %
90.19%
Holding
19
New
1
Increased
–
Reduced
–
Closed
–
Avg Time Held
1.2
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aurinia Pharmaceuticals
AUPH
|
+$214K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Miscellaneous | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
PRTK
1
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $19.7M | 18.31% |
1,301,413
| – | – |
2014 Q4
5 quarters
|
|
|
CHMA
2
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $19M | 17.69% |
2,080,595
| – | – |
2015 Q3
2 quarters
|
|
3
Protara Therapeutics
TARA
$150M
| $15.6M | 14.46% |
50,447
| – | – |
2014 Q4
5 quarters
|
|
|
SIEN
4
DELISTED
Sientra, Inc.
SIEN
| $15M | 13.98% |
219,901
| – | – |
2014 Q4
5 quarters
|
|
|
CEMP
5
DELISTED
Cempra, Inc.
CEMP
| $6.72M | 6.25% |
383,935
| – | – |
2013 Q2
11 quarters
|
|
|
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5.06M | 4.7% |
945,757
| – | – |
2014 Q1
8 quarters
|
|
|
TBRA
7
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $4.78M | 4.45% |
589,244
| – | – |
2015 Q2
3 quarters
|
|
|
INNL
8
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
| $4.67M | 4.34% |
555,555
| – | – |
2015 Q2
3 quarters
|
|
|
EVAR
9
DELISTED
Lombard Medical, Inc.
EVAR
| $3.75M | 3.49% |
3,473,452
| – | – |
2014 Q3
6 quarters
|
|
10
Cellectis
CLLS
$134M
| $2.74M | 2.54% |
100,000
| – | – |
2015 Q4
1 quarter
|
|
11
DELISTED
Regulus Therapeutics
RGLS
| $2.26M | 2.1% |
2,728
| – | – |
2014 Q1
8 quarters
|
|
12
DELISTED
Cymabay Therapeutics
CBAY
| $2.16M | 2.01% |
1,600,000
| – | – |
2015 Q3
2 quarters
|
|
|
ADAP
13
DELISTED
Adaptimmune Therapeutics
ADAP
| $2.03M | 1.88% |
250,000
| – | – |
2015 Q4
1 quarter
|
|
|
ANTH
14
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $1.58M | 1.47% |
54,749
| – | – |
2013 Q2
11 quarters
|
|
15
DELISTED
Dermira, Inc.
DERM
| $1.45M | 1.35% |
70,000
| – | – |
2015 Q3
2 quarters
|
|
16
DELISTED
ChemoCentryx, Inc.
CCXI
| $533K | 0.5% |
215,000
| – | – |
2015 Q1
4 quarters
|
|
17
Achieve Life Sciences
QUIT
$692M
| $271K | 0.25% |
180
| – | – |
2013 Q2
11 quarters
|
|
|
18
Aurinia Pharmaceuticals
AUPH
$2.17B
| $256K | 0.24% |
+88,307
| New | +$214K |
2016 Q1
0 quarters
|
|
|
EPRS
19
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $21K | 0.02% |
7,896
| – | – |
2015 Q3
2 quarters
|
|
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q1 2016 Portfolio in Review
As of Q1 2016, Abingworth held 19 positions worth $108M, down 35% from $166M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Abingworth's Q1 2016 filing shows 1 new position. Its largest new stake was Aurinia Pharmaceuticals: 88,307 shares worth $256K.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
- Abingworth's largest Q1 2016 buy was Aurinia Pharmaceuticals: 88,307 shares worth $256K.
- Abingworth's ten largest holdings make up 90% of its $108M portfolio in Q1 2016.
- Abingworth opened 1 new position and closed 0 in Q1 2016.
- Abingworth's portfolio value fell 35% quarter-over-quarter to $108M.
Based on Abingworth's 13F filing for Q1 2016, filed 13 May 2016.